Emerging combination therapies for the management of multiple myeloma: the role of elotuzumab.

Chen, Wei-Chih; Kanate, Abraham S; Craig, Michael; Petros, William P; Hazlehurst, Lori A

Chen, Wei-Chih; Kanate, Abraham S; Craig, Michael; Petros, William P; Hazlehurst, Lori A.

Afiliação

Chen WC; Department of Pharmaceutical Sciences, School of Pharmacy.
Kanate AS; Osborn Hematopoietic Malignancy and Transplantation Program, West Virginia University.
Craig M; West Virginia University Cancer Institute, Morgantown, WV, USA.
Petros WP; Osborn Hematopoietic Malignancy and Transplantation Program, West Virginia University.
Hazlehurst LA; West Virginia University Cancer Institute, Morgantown, WV, USA.

Cancer Manag Res ; 9: 307-314, 2017.

Article em En | MEDLINE | ID: mdl-28744161

Palavras-chave

SLAMF7; elotuzumab; relapsed/refractory multiple myeloma (RRMM)

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Cancer Manag Res Ano de publicação: 2017 Tipo de documento: Article